The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: A meta-analysis of prospective randomized trials

Oncologist

Volumn 20, Issue 3, 2015, Pages 307-315

  Hasegawa, Yoshikazu ^a   Ando, Masahiko ^b   Maemondo, Makoto ^c   Yamamoto, Satomi ^d   Isa, Shun Ichi ^e   Saka, Hideo ^f   Kubo, Akihito ^g   Kawaguchi, Tomoya ^h   Takada, Minoru ⁱ   Rosell, Rafael ^j   Kurata, Takayasu ^k   Ignatius Ou, Sai Hong ^l  

^a Izumi Municipal Hospital   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c Miyagi Cancer Center   (Japan)

^d UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^e NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^g AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ Koyo Hospital   (Japan)

^j CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^k KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Afatinib; EGFR mutant non small cell lung cancer; EGFR TKIs; Erlotinib; Gefitinib; Meta analysis; Smoking status

Indexed keywords

AFATINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ARTICLE; GENE MUTATION; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SURVIVAL RATE;

EID: 84925393659     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0285     Document Type: Article

References (27)

1. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growthfactorreceptor(WJTOG3405):An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–128.
2. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380–2388.
3. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multi-centre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735–742.
4. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-celllung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–246.
5. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327–3334.
6. 6.Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancerharbouring EGFR mutations (LUX-Lung 6):An open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213–222.
7. 7.Wu YL, Liam CK, Zhou C et al. First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): Interim analysis from the phase 3, open-label, ENSURE study. J Thorac Oncol 2013;8(suppl 2):S603.
8. Ou SH. Lung cancer in never-smokers: Does smoking history matter in the era of molecular diagnostics and targeted therapy? J Clin Pathol 2013;66:839–846.
9. Oizumi S, Kobayashi K, Inoue A et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: Quality of life analysis of North East Japan Study Group 002 Trial. The Oncologist 2012;17:863–870.
10. Inoue A, Kobayashi K, Maemondo M et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-näıve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013;24:54–59.
11. Imielinski M, Berger AH, Hammerman PS etal. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150: 1107–1120.
12. Govindan R, Ding L, Griffith M et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-1134.
13. Filosto S, Baston DS, Chung S et al. Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells. Mol Cancer Ther 2013;12:1579-1590.
14. Wang S, Takayama K, Tanaka K et al. Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by a1 nicotinic acetylcholine receptor-mediated activation in PC9 cells. J Thorac Oncol 2013;8:719-725.
15. Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12:2166-2171.
16. Hughes AN, O’Brien MER, Petty WJ et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009;27:1220-1226.
17. Kim MH, Kim HR, Cho BC et al. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Lung Cancer 2014;84:196-202.
18. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
19. Han JY, Park K, Kim S W et al. First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-1128.
20. Mulloy R, Ferrand A, Kim Y et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007; 67:2325-2330.
21. Carey KD, Garton AJ, Romero MS et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66: 8163-8171.
22. Riely GJ, Pao W, Pham D et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-844.
23. Jackman DM, Yeap BY, Sequist LV et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12: 3908-3914.
24. Liang W Sheng J, Wu X et al. Exon 19 deletion association with progression-free survival compared to L858R mutation at exon 21 in treatment with first-line EGFR-TKIs: A meta-analysis of subgroup data from eight phase III randomized controlled trials. J Clin Oncol 2014;32(suppl):8107a.
25. Yang JC, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015 [Epub ahead of print].
26. Liam CK, Wahid MIA, Rajadurai P et al. Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients. J Thorac Oncol 2013;8:766-772.
27. Shi Y, Au JS, Thongprasert S et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014;9:154-162.